This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
Durata Therapeutics (NASDAQ: DRTX) today announced
in vitro study data that could help support a clinical development program to investigate its lead product candidate, dalbavancin, for the treatment of pneumonia. In this study, lung surfactant did not have a significant impact on the
in vitro susceptibility of
Staphylococcus aureus and
Streptococcus pneumoniae to dalbavancin.
“We wanted to understand if surfactant would affect the potency of dalbavancin against bacteria of most concern to clinicians treating pneumonia patients,” said Durata Therapeutics Chief Medical Officer Michael Dunne, M.D. “These data validate our assumption that surfactant does not significantly impact the
in vitro potency of dalbavancin.”
Dalbavancin is currently under investigation in two ongoing, global, Phase 3 clinical trials for the treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible gram-positive bacteria.
The data from the study [
The effect of lung surfactant on the in vitro activity of dalbavancin against Staphylococcus aureus and Streptococcus pneumoniae (Dunne, et al). Poster Number 1622] are being presented at the Novel Antimicrobial Agents session of IDWeek in San Diego. IDWeek is the first-ever combined meeting of four prestigious societies: the Infectious Diseases Society of America (IDSA), the Society for Healthcare Epidemiology of America (SHEA), the HIV Medicine Association (HIVMA), and the Pediatric Infectious Diseases Society (PIDS).
Durata will display data from this and another dalbavancin-related study (Poster Number 1624) in San Diego Convention Center Halls F-H from Thursday, October 18 at 9:30 a.m. until Saturday, October 20 at 6:00 p.m. Dr. Dunne and co-presenting author Laura Koeth will be at the poster for discussion on Saturday, October 20, 12:30 – 2:00 p.m. PT.
For more information on the two studies presented at IDWeek 2012, visit
Dalbavancin is an intravenous antibiotic product candidate under investigation for once-weekly dosing, which we believe may facilitate the treatment of patients with ABSSSI in both the in-patient and out-patient settings, potentially reducing the length of a patient’s hospital stay or avoiding hospital admission altogether, with an impact on the overall cost of care for these patients.